50
Participants
Start Date
October 20, 2022
Primary Completion Date
March 27, 2025
Study Completion Date
March 31, 2026
Prednisone
Prednisone starting dose of 0.5 mg/kg; for patients who respond clinically and continue to have low biomarkers will be tapered rapidly; those that are not clinically responding or whose biomarkers increase will be treated per their treating physicians plan or by standard of care
Icahn School of Medicine at Mount Sinai, New York
Memorial Sloan Kettering Cancer Center, New York
Children's Hospital of Philadelphia, Philadelphia
Children's National Hospital, Washington D.C.
Children's Healthcare of Atlanta, Atlanta
Vanderbilt University Medical Center, Nashville
Medical College of Wisconsin / Children's Wisconsin, Milwaukee
Texas Children's Hospital, Baylor College of Medicine, Houston
Children's Hospital of Los Angeles, Los Angeles
Boston Children's Hospital Dana Farber Cancer Institute, Boston
The Hospital for Sick Children, Toronto
John Levine
OTHER